Summary

Eligibility
for females ages 18 years and up (full criteria)
Location
at UC Davis UCSD
Dates
study started
study ends around

Description

Summary

This phase I trial studies how well atezolizumab before and/or with standard of care chemoradiotherapy works in immune system activation in patients with stage IB2, II, IIIB, or IVA cervical cancer that has spread to the lymph nodes. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving atezolizumab before and/or with chemoradiotherapy may lower the chance of tumors growing or spreading.

Official Title

Anti PD-L1 (Atezolizumab) as an Immune Primer and Concurrently With Extended Field Chemoradiotherapy for Node Positive Locally Advanced Cervical Cancer

Details

Keywords

Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Stage IB2 Cervical Cancer AJCC v8, Stage II Cervical Cancer AJCC v8, Stage IIA Cervical Cancer AJCC v8, Stage IIA1 Cervical Cancer AJCC v8, Stage IIA2 Cervical Cancer AJCC v8, Stage IIB Cervical Cancer AJCC v8, Stage IIIB Cervical Cancer AJCC v8, Stage IVA Cervical Cancer AJCC v8, Carcinoma, Uterine Cervical Neoplasms, Adenosquamous Carcinoma, Cisplatin, Atezolizumab, Monoclonal Antibodies, Brachytherapy, Radiation Therapy

Eligibility

Locations

  • UC San Diego Moores Cancer Center
    La Jolla California 92093 United States
  • University of California Davis Comprehensive Cancer Center
    Sacramento California 95817 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
National Cancer Institute (NCI)
ID
NCT03738228
Phase
Phase 1 research study
Study Type
Interventional
Participants
About 40 people participating
Last Updated